However, in the case of 150 mpk CTX-treated mice, IL7-Fc further suppressed tumor growth rate, but percentages of pmel-1 Thy1.1+CD8+ TILs were comparable in both hIgG- or IL7-Fc treated mice at day 13 and 19, while endogenous Thy1.1−CD8+ TILs were still significantly increased by IL7-Fc treatment at day 19, which indicate that IL7-Fc-mediated anti-tumor immunity under lymphopenic condition may include the increase of tumor-reactive endogenous CD8+ T cells. The gene discussed is IL7; the disease is neoplasm.